Johnson & Johnson – Johnson & Johnson (NYSE:JNJ) Expected to Announce Quarterly Sales of $21.82 Billion

Wall Street analysts expect that Johnson & Johnson (NYSE:JNJ) will report sales of $21.82 billion for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Johnson & Johnson’s earnings, with the lowest sales estimate coming in at $21.44 billion and the highest estimate coming in at $22.05 billion. Johnson & Johnson reported sales of $20.75 billion during the same quarter last year, which indicates a positive year over year growth rate of 5.2%. The firm is scheduled to issue its next earnings results before the market opens on Tuesday, January 26th.

According to Zacks, analysts expect that Johnson & Johnson will report full-year sales of $81.93 billion for the current fiscal year, with estimates ranging from $81.55 billion to $82.16 billion. For the next fiscal year, analysts anticipate that the business will report sales of $88.67 billion, with estimates ranging from $87.57 billion to $90.10 billion. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that cover Johnson & Johnson.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.98 by $0.22. The company had revenue of $21.08 billion during the quarter, compared to analysts’ expectations of $20.15 billion. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The firm’s quarterly revenue was up 1.7% on a year-over-year basis. During the same period in the prior year, the business earned $2.12 EPS.

JNJ has been the subject of several analyst reports. Morgan Stanley upped their target price on Johnson & Johnson from $170.00 to $178.00 and gave the company an “overweight” rating in a report on Tuesday, December 15th. BidaskClub cut Johnson & Johnson from a “sell” rating to a “strong sell” rating in a report on Monday, December 28th. Cantor Fitzgerald upped their target price on Johnson & Johnson from $168.00 to $180.00 and gave the company an “overweight” rating in a report on Wednesday, October 14th. Credit Suisse Group upped their price target on Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a research note on Wednesday, October 14th. Finally, Raymond James reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Friday, November 20th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and ten have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $165.50.

Shares of NYSE:JNJ opened at $157.38 on Friday. The company has a quick ratio of 1.24, a current ratio of 1.48 and a debt-to-equity ratio of 0.51. The business has a fifty day moving average of $149.97 and a two-hundred day moving average of $147.22. The stock has a market cap of $414.31 billion, a P/E ratio of 24.75, a PEG ratio of 3.30 and a beta of 0.68. Johnson & Johnson has a 52-week low of $109.16 and a 52-week high of $157.66.

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th were paid a dividend of $1.01 per share. This represents a $4.04 annualized dividend and a yield of 2.57%. The ex-dividend date was Monday, November 23rd. Johnson & Johnson’s payout ratio is 46.54%.

In related news, COO Michael E. Sneed sold 54,662 shares of the stock in a transaction dated Wednesday, December 9th. The stock was sold at an average price of $152.93, for a total transaction of $8,359,459.66. Following the transaction, the chief operating officer now owns 110,741 shares of the company’s stock, valued at approximately $16,935,621.13. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.27% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of JNJ. Newfound Research LLC acquired a new stake in Johnson & Johnson in the 3rd quarter valued at about $28,000. Essex Investment Management Co. LLC acquired a new stake in Johnson & Johnson in the 3rd quarter valued at about $37,000. HWG Holdings LP acquired a new stake in Johnson & Johnson in the 2nd quarter valued at about $49,000. Crewe Advisors LLC raised its position in Johnson & Johnson by 909.1% in the 3rd quarter. Crewe Advisors LLC now owns 333 shares of the company’s stock valued at $50,000 after purchasing an additional 300 shares in the last quarter. Finally, Dimension Capital Management LLC acquired a new stake in Johnson & Johnson in the 3rd quarter valued at about $53,000. 61.26% of the stock is currently owned by institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON’S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More: Conference Calls

Get a free copy of the Zacks research report on Johnson & Johnson (JNJ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]